Overview

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the safety and tolerability of multiple oral doses of E6742 in participants with systemic lupus erythematosus (SLE).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eisai Co., Ltd.